Latest ArticlesThe effects of the crystallization temperature, the dripping rate of antisolvent adding, the initial concentration of the crystallization and the occasion of seed crystal adding on the polymorph formation of fusidic acid(1) were investigated by the orthogonal experiment. The results showed that the crystallization temperature was the key factor affecting the polymorph formation of 1, followed by the dripping rate of antisolvent. Anhydrous 1 was formed when the antisolvent dripping rate was 0.1 ml/min and crystallized at 40 ℃, while 1 hemihydrate was obtained with more than 0.2 ml/min of dripping rate and 20 – 30 ℃ of crystallization temperature. The crystallization process of 1 was recorded online in real time with process analysis technology tools, and the transformation process of 1 crystal forms was revealed. Powder X-ray diffractometry(PXRD) and infrared spectroscopy(IR) were applied for both anhydrate and hemihydrate products. The analysis results were consistent with the literature reports. The experimental results could provide technical guidance for the large-scale production of 1 hemihydrate.
The Arrhenius equation was used to predict the impurity growth trend of dexrazoxane for injection. The levels of impurities A and B were measured at 50, 60, 65, 75 and 80 ℃, and the rate constant(k) values for both was calculated. The Arrhenius equation of impurity A was lnk=–9.612–3.7/T(R2=0.953 8, P<0.000 1), and the Arrhenius equation of impurity B was lnk=–7.546–2.3/T(R2=0.959 1, P<0.000 1) by standard least squares linear regression. Then, the obtained Arrhenius equations were used to predict the levels of impurities A and B of 3 pilot batches of dexrazoxane for injection stored at 25 ℃ for 12 months, and the deviations of the predicted and measured values of impurity A were 0, 16.67% and 0, while the deviations of the predicted and measured values of impurity B were 4.76%,5.26% and 5.56%, respectively. It was predicted that the levels of impurities A and B in dexrazoxane for injection stored at 25 ℃ were below limits in 51 months. The Arrhenius equation established in this paper can effectively predict the growth of impurities A and B of dexrazoxane for injection, which can be used as data support for the stability study of this product.
The production mode of oral solid dosage forms is gradually changing from batch to continuous manufacturing. Using process analysis technology to analyze and control the critical quality attributes of raw materials, intermediate products and final products can realize high efficiency manufacturing, automatic monitoring, high product quality requirements and real-time release testing. Continuous manufacturing which integrates continuous production lines, process analysis technology and advanced feedback control system is more in line with the concept of pharmaceutical industry 4.0. In this paper, the development and status, the preparation process and application of process analysis technology in oral solid dosage forms are reviewed to provide references for further research.
Protein and peptide drugs(PPDs) have good specificity, biocompatibility and good therapeutic effects. Due to the better patient compliance and safety of oral administration route, the oral delivery of PPDs has become one of the current research hotspots in the field of materials science and pharmaceuticals. However, the stability and absorption of oral biomacromolecules in the gastrointestinal tract are restricted. Lipid nanocarriers can effectively encapsulate lipophilic or hydrophilic PPDs through chemical modification, hydrophobic ion pairing and other methods. At the same time, the surface modification of lipid nanocarriers can overcome many physiological barriers of the oral absorption, which in turn promote the dissolution of PPDs in mixed micelles and strengthen lymphatic uptake. Therefore, it has good biocompatibility and high in vivo stability. In this paper, the encapsulation methods of lipid nanocarriers for PPDs and the corresponding mechanisms of overcoming physiological barriers are reviewed, and the important properties and latest research progress of lipid nanocarriers to improve the oral bioavailability of PPDs are introduced, the potential application and development prospects are further prospected as well.
Wet media milling technology, with the advantages of simple operation, avoiding the use of organic solvents, and high drug loading, has been proven to be a preparation technology for bioavailability enhancement of poorly water-soluble drugs, especially for injectable nanosuspensions. This review summarizes the research progress of injectable nanosuspension prepared by wet media milling technology and introduces the active pharmaceutical ingredients, stabilizers, dispersants, and cryoprotectants. The process parameters and critical quality attributes are also analyzed to provide a basis for the research and development of injectable nanosuspensions prepared by wet media milling technology, so as to promote the transition of safe, effective, quality-controllable injectable nanosuspensions from experimental research to clinical applications at a faster speed.
Oral administration, with the characteristics of high safety and economic convenience, is one of the most common ways of drug delivery. However, the substantial discrepancy between potent therapeutic properties of various medicines and their low oral bioavailability limits their application. In recent years, researches have revealed that gut microbiota, which act as a practical bioreactor in the human intestinal tract, have an essential effect on the discrepancy. In addition to directly participating in drug metabolism through biotransformation, gut microbiota can also indirectly affect bioavailability of oral drugs by regulating the expression levels of host liver metabolic enzymes and the transporters. This review briefly introduces the factors affecting drug bioavailability, and mainly discusses the effects of gut microbiota and probiotics on drug oral bioavailability to provide a reference for understanding the relationship between gut microbiota and drug oral bioavailability, and developing novel strategies for improving drug oral bioavailability.
In this paper, the drug finerenone for diabetic nephropathy treatment was synthesized. Firstly, the intermidate ethyl 2-cyanoacetoacetate(6) was prepared with 3,5,5-trimethyl-4,6-dioxacyclohex-2-en-1-one(16) and 3-hydroxypropionitrile, and then react with 4-cyano-2-methoxybenzyaldehyde and 4-amino-5-methylpyridin-2-ol via continuous Knoevenagel condensation and Hantzsch cyclization, respectively. Finally, finerenone was obtained via O-alkylation, hydrolysis, ammonolysis and chiral column resolution with an overall yield of 30.8% (based on 16), and 99.7% HPLC purity as well as 99.4% ee value. The improved process had the advantages of simple operation, mild condition, high yield and low cost.
Ethyl (1R,5S,6S)-5-(pentan-3-yloxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate(2) was the key starting material of oseltamivir phosphate(1). Compound 3, the (1R,5R,6R)-diastereomer of 2, was synthesized as the standard control to evaluate the chiral purity of 2 as well as 1. With shikimic acid as starting material, compound 3 was obtained through esterification, 3-pentanone protection, 5-hydroxybenzylation, reductive ring opening of the ketals,4-hydroxymethylsulfonylation, and alkalic hydrolysis. The structure was conformed by 1H NMR, 13C NMR and ESI-MS.